Detalhe da pesquisa
1.
Relationship between quantitative strength and functional outcomes in the phase 2 FORTITUDE-ALS trial.
Amyotroph Lateral Scler Frontotemporal Degener
; 25(1-2): 162-169, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-37641579
2.
Time from amyotrophic lateral sclerosis symptom onset to key disease milestones: analysis of data from a multinational cross-sectional survey.
Amyotroph Lateral Scler Frontotemporal Degener
; 25(3-4): 345-357, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38156828
3.
MiToS and King's staging as clinical outcome measures in ALS: a retrospective analysis of the FORTITUDE-ALS trial.
Amyotroph Lateral Scler Frontotemporal Degener
; 24(3-4): 304-310, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36503310
4.
Health utilities and quality-adjusted life years for patients with amyotrophic lateral sclerosis receiving reldesemtiv or placebo in FORTITUDE-ALS.
J Med Econ
; 26(1): 488-493, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36930042
5.
COURAGE-ALS: a randomized, double-blind phase 3 study designed to improve participant experience and increase the probability of success.
Amyotroph Lateral Scler Frontotemporal Degener
; 24(5-6): 523-534, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37254449
6.
Prescription and acceptance of durable medical equipment in FORTITUDE-ALS, a study of reldesemtiv in ALS: post hoc analyses of a randomized, double-blind, placebo-controlled clinical trial.
Amyotroph Lateral Scler Frontotemporal Degener
; 23(3-4): 263-270, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-34218726
7.
Noninvasive ventilation use by patients enrolled in VITALITY-ALS.
Amyotroph Lateral Scler Frontotemporal Degener
; 22(7-8): 486-494, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-33792451
8.
Reldesemtiv in Patients with Spinal Muscular Atrophy: a Phase 2 Hypothesis-Generating Study.
Neurotherapeutics
; 18(2): 1127-1136, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33624184
9.
Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III.
Ann Neurol
; 66(2): 235-44, 2009 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-19743457
10.
Prevention and treatment of peripheral neuropathy after bariatric surgery.
Curr Treat Options Neurol
; 12(1): 29-36, 2010 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-20842487
11.
A phase III trial of tirasemtiv as a potential treatment for amyotrophic lateral sclerosis.
Amyotroph Lateral Scler Frontotemporal Degener
; 0(0): 1-11, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31081694
12.
The importance of a respiratory therapist in the ALS clinic.
Amyotroph Lateral Scler
; 9(3): 173-6, 2008 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-17924238
13.
Association Between Decline in Slow Vital Capacity and Respiratory Insufficiency, Use of Assisted Ventilation, Tracheostomy, or Death in Patients With Amyotrophic Lateral Sclerosis.
JAMA Neurol
; 75(1): 58-64, 2018 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29181534
14.
Understanding the use of NIV in ALS: results of an international ALS specialist survey.
Amyotroph Lateral Scler Frontotemporal Degener
; 19(5-6): 331-341, 2018 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29661084
15.
Editorial to the supplement entitled "assessments of pulmonary function in patients with amyotrophic lateral sclerosis: options and applicability in both the clinical care and clinical trial settings".
Amyotroph Lateral Scler Frontotemporal Degener
; 22(sup1): 2-4, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34348532
16.
Correction to: Reldesemtiv in Patients with Spinal Muscular Atrophy: a Phase 2 Hypothesis-Generating Study.
Neurotherapeutics
; 18(3): 2130, 2021 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-34731415
17.
Racial differences in motor neuron disease.
Amyotroph Lateral Scler Frontotemporal Degener
; 15(1-2): 114-8, 2014 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-24067242
18.
A post hoc analysis of subgroup outcomes and creatinine in the phase III clinical trial (EMPOWER) of dexpramipexole in ALS.
Amyotroph Lateral Scler Frontotemporal Degener
; 15(5-6): 406-13, 2014 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-25125035
19.
Clinical variability and female penetrance in X-linked familial FTD/ALS caused by a P506S mutation in UBQLN2.
Amyotroph Lateral Scler Frontotemporal Degener
; 14(7-8): 615-9, 2013 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-23944734
20.
Dexpramipexole effects on functional decline and survival in subjects with amyotrophic lateral sclerosis in a Phase II study: subgroup analysis of demographic and clinical characteristics.
Amyotroph Lateral Scler Frontotemporal Degener
; 14(1): 44-51, 2013 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-22985432